Shehnaaz Suliman, ReCode Therapeutics CEO (Photo by Jennifer Leahy)
June 29, 2022 06:00 AM EDTUpdated 06:56 AM
Financing

Pfiz­er, Sanofi-backed LNP out­fit goes back to the well and draws $120M for its trek to the clin­ic

Paul Schloesser

Associate Editor

A pre­clin­i­cal biotech tout­ing a five-lipid drug de­liv­ery plat­form is look­ing to break out of its pre­clin­i­cal mold, and it just se­cured a siz­able raise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times